Chinook Therapeutics Inc expected to post a loss of 61  cents a share - Earnings Preview

Chinook Therapeutics

29/07/2022 12:06

* Chinook Therapeutics Inc  KDNY.OQ   KDNY.O  is expected
to show
a rise in quarterly revenue when it reports  results on August 1
(estimated). 
    * The Seattle Washington-based  company is expected to
report  a
1,125.5% increase in revenue to $416.67 thousand from $34
thousand a year ago, according to the mean estimate from 6
analysts, based on Refinitiv data. 
    * ​Refinitiv's mean analyst estimate for Chinook
Therapeutics Inc
is for a loss of 61 cents per share. For the same quarter last
year, the company reported a loss of $1.14 per share.
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 9 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Chinook
Therapeutics Inc is $31.5​, above​ its last closing price
of $18.68. ​​​
    * Previous quarterly performance (using preferred earnings
measure
in US dollars). ​

 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Mar. 31 2022  -0.66       -0.67      -0.54     Beat    18.9
 Dec. 31 2022  -0.75       -0.68      0.14      Beat    120.7
 Sep. 30 2021  -0.88       -0.84      -0.69     Beat    17.7​
 Jun. 30 2021  -0.79       -0.78      -1.14     Missed  -45.5
 ​​Mar.        -0.65       -0.68      -0.88     Missed  -30
 31 2021                                                
 Dec. 31 2020  -0.51       -0.44      -1.24     Missed  -178.7
                                                        ​
 Sep. 30 2020  -0.49       -0.45      -0.90     Missed  -97.8
 Jun. 30 2020  -1.01       -0.95      -1.05     Missed  -10.5
 This summary was machine generated July 29 at 11:06 GMT.  All
figures in US dollars  unless otherwise stated